Revumenib: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description| | {{Short description|Overview of the drug Revumenib}} | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 123456789 | ||
| image = Revumenib.svg | | image = Revumenib.svg | ||
| image2 = | | image2 = | ||
| width = 200 | | width = 200 | ||
| alt = | |||
| caption = Chemical structure of Revumenib | |||
}} | }} | ||
'''Revumenib''' is | '''Revumenib''' is an investigational drug that acts as an inhibitor of the [[menin-MLL interaction]], which is implicated in certain types of [[acute leukemia]]. It is being studied for its potential use in treating [[acute myeloid leukemia]] (AML) and [[acute lymphoblastic leukemia]] (ALL) with specific genetic mutations. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revumenib functions by inhibiting the interaction between menin | Revumenib functions by inhibiting the interaction between [[menin]] and [[mixed-lineage leukemia]] (MLL) proteins. This interaction is crucial for the proliferation of leukemia cells that harbor [[MLL rearrangements]] or [[NPM1 mutations]]. By disrupting this interaction, Revumenib aims to halt the growth of these cancerous cells and induce apoptosis. | ||
==Clinical Development== | ==Clinical Development== | ||
Revumenib is currently undergoing clinical trials to evaluate its efficacy | Revumenib is currently undergoing clinical trials to evaluate its safety and efficacy in patients with relapsed or refractory AML and ALL. These trials are particularly focused on patients with MLL rearrangements or NPM1 mutations, as these genetic alterations are known to drive the pathogenesis of these leukemias. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
The pharmacokinetic profile of | The pharmacokinetic profile of Revumenib is characterized by its absorption, distribution, metabolism, and excretion properties. It is designed to be administered orally, allowing for convenient dosing in a clinical setting. The drug's metabolism and elimination pathways are being studied to optimize its therapeutic window and minimize potential side effects. | ||
==Potential Side Effects== | ==Potential Side Effects== | ||
As with many | As with many investigational drugs, Revumenib may have side effects. Commonly observed adverse effects in clinical trials include [[cytopenias]], [[gastrointestinal disturbances]], and [[fatigue]]. Ongoing studies aim to further elucidate the safety profile of Revumenib and manage any adverse reactions effectively. | ||
== | ==Future Directions== | ||
The development of Revumenib represents a promising advance in the targeted treatment of leukemias with specific genetic profiles. Future research will focus on combination therapies, resistance mechanisms, and expanding the indications for Revumenib to include other hematological malignancies. | |||
==Related Pages== | ==Related Pages== | ||
* [[Acute myeloid leukemia]] | * [[Acute myeloid leukemia]] | ||
* [[Acute lymphoblastic leukemia]] | * [[Acute lymphoblastic leukemia]] | ||
* [[Menin- | * [[Menin]] | ||
* [[ | * [[Mixed-lineage leukemia]] | ||
* [[NPM1 mutation]] | |||
[[Category:Experimental cancer drugs]] | [[Category:Experimental cancer drugs]] | ||
[[Category:Leukemia treatments]] | |||
Latest revision as of 19:13, 6 March 2025
Overview of the drug Revumenib
| Revumenib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Revumenib is an investigational drug that acts as an inhibitor of the menin-MLL interaction, which is implicated in certain types of acute leukemia. It is being studied for its potential use in treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with specific genetic mutations.
Mechanism of Action[edit]
Revumenib functions by inhibiting the interaction between menin and mixed-lineage leukemia (MLL) proteins. This interaction is crucial for the proliferation of leukemia cells that harbor MLL rearrangements or NPM1 mutations. By disrupting this interaction, Revumenib aims to halt the growth of these cancerous cells and induce apoptosis.
Clinical Development[edit]
Revumenib is currently undergoing clinical trials to evaluate its safety and efficacy in patients with relapsed or refractory AML and ALL. These trials are particularly focused on patients with MLL rearrangements or NPM1 mutations, as these genetic alterations are known to drive the pathogenesis of these leukemias.
Pharmacokinetics[edit]
The pharmacokinetic profile of Revumenib is characterized by its absorption, distribution, metabolism, and excretion properties. It is designed to be administered orally, allowing for convenient dosing in a clinical setting. The drug's metabolism and elimination pathways are being studied to optimize its therapeutic window and minimize potential side effects.
Potential Side Effects[edit]
As with many investigational drugs, Revumenib may have side effects. Commonly observed adverse effects in clinical trials include cytopenias, gastrointestinal disturbances, and fatigue. Ongoing studies aim to further elucidate the safety profile of Revumenib and manage any adverse reactions effectively.
Future Directions[edit]
The development of Revumenib represents a promising advance in the targeted treatment of leukemias with specific genetic profiles. Future research will focus on combination therapies, resistance mechanisms, and expanding the indications for Revumenib to include other hematological malignancies.
